Starting HIV prevention and addiction treatment while in jail
Treatments studied
Part of Immune system & allergy, Infections, Mental health clinical trials.
This study tests a better way to start long-acting HIV prevention (PrEP) and buprenorphine for opioid use disorder while people are in jail, to see if it helps them stay healthy after release. If you are soon leaving jail and have opioid use disorder, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and currently in jail or prison.
- Your release is expected within the next 120 days, and you are not going to federal prison.
- You have a history of opioid use disorder (addiction to pain pills, heroin, or fentanyl) or have been on medication treatment for it recently.
- You are not currently infected with HIV, and you are eligible for HIV prevention medication (PrEP).
- You are willing to take buprenorphine for opioid addiction and PrEP, and you will live in the study area after release.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
This trial offers buprenorphine (a medication for opioid use disorder) to people in jail who are soon to be released. It helps you start treatment while incarcerated and continue it after you return to the community, aiming to reduce overdose and improve recovery.
This study helps people who inject drugs start HIV prevention (PrEP) and medication for opioid use disorder (MOUD) faster. It may reduce HIV risk and improve access to treatment, while the study checks whether the “rapid access” approach works.
This study tests an integrated phone-based health program (e-health) designed for women involved with the justice system who have opioid use disorder. It aims to help people who qualify for HIV prevention (PrEP) stay protected, especially by using simple, ongoing support through phone access.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
This study tests whether a once-monthly injection of buprenorphine (called extended-release buprenorphine, or XR-B) works well for people in prison who are already in a medication program for opioid use disorder. It looks at preferences and outcomes in the last months before release.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.